Biological activity of acyclonucleosides

[1]  D. Smee,et al.  Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. , 1997, Antiviral research.

[2]  C. Monneret,et al.  Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). , 1997, Journal of medicinal chemistry.

[3]  H. Tsubouchi,et al.  Progressive retinitis-encephalitis due to ganciclovir-resistant cytomegalovirus associated with aplastic anemia. , 1997, Internal medicine.

[4]  I. Votruba,et al.  Antitumor activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP. , 1997, In Vivo.

[5]  H. Pelicano,et al.  Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. , 1996, Journal of medicinal chemistry.

[6]  T. Cihlar,et al.  Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. , 1996, Molecular pharmacology.

[7]  A. Gotoh,et al.  Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells. , 1996, Leukemia research.

[8]  S. Tyring,et al.  Famciclovir: review of clinical efficacy and safety. , 1996, Antiviral research.

[9]  E. De Clercq,et al.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine , 1996, Antimicrobial agents and chemotherapy.

[10]  J. Imbach,et al.  Increase of the anti-HIV activity of D4T in human T-cell culture by the use of the sate pronucleotide approach , 1995 .

[11]  K. Beutner,et al.  Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. , 1995, Antiviral research.

[12]  K. H. Kim,et al.  Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy] guanine against cytomegalovirus and herpes simplex virus. , 1995, Antiviral research.

[13]  J. Imbach,et al.  Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate. , 1995, Journal of medicinal chemistry.

[14]  T. Burnette,et al.  Purification and Characterization of a Rat Liver Enzyme That Hydrolyzes Valaciclovir, the L-Valyl Ester Prodrug of Acyclovir (*) , 1995, The Journal of Biological Chemistry.

[15]  M. Kurokawa,et al.  Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV. , 1995, Antiviral research.

[16]  R. T. Walker,et al.  Hept Derivatives: 6-Benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442) , 1995 .

[17]  M. Connelly,et al.  Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. , 1995, Molecular pharmacology.

[18]  A. Glazier,et al.  Potent topical anti-herpes activity of a lipophilic phosphorus prodrug for the antiviral agent PMEA , 1995 .

[19]  Y. Yoshimura,et al.  Comparison of the Selectivity of Anti‐Varicella‐Zoster Virus Nucleoside Analogues , 1995, Microbiology and immunology.

[20]  E. De Clercq,et al.  (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection , 1995, Antimicrobial agents and chemotherapy.

[21]  D. Ilsley,et al.  Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. , 1995, Biochemistry.

[22]  L. Naesens,et al.  IN VIVO ANTIRETROVIRAL EFFICACY OF ORAL BIS(POM)-PMEA, THE BIS(PIVALOYLOXYMETHYL)PRODRUG OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) , 1995 .

[23]  H. Mitsuya,et al.  Synthesis and Anti-HIV Activity of 5-Fluorocytallene: N-Dimethylaminomethylene as a Facilitating Group in Acetylene → Allene Isomerization , 1994 .

[24]  J. Phair,et al.  The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study , 1994, Annals of Internal Medicine.

[25]  H. Pelicano,et al.  Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine. , 1994, Biochemical pharmacology.

[26]  J. C. Martin,et al.  Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). , 1994, Journal of medicinal chemistry.

[27]  R. Sidwell,et al.  Synthesis of Acyclonucleoside Phosphonates as Antiviral Agents Against Cytomegalovirus , 1994 .

[28]  R. Sidwell,et al.  Structure-Activity Relationship of Phosphonic Acid Analogs of Acyclovir or Ganciclovir Against Human Cytomegalovirus in MRC-5 Cells , 1994 .

[29]  A K Field,et al.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs , 1994, Clinical Microbiology Reviews.

[30]  A. Holý,et al.  Preparation of 9-(2-phosphonomethoxyethyl)adenine esters as potential prodrugs , 1994 .

[31]  J. Imbach,et al.  Rational design for cytosolic delivery of nucleoside monphosphates : “SATE” and “DTE” as enzyme-labile transient phosphate protecting groups , 1993 .

[32]  J. Imbach,et al.  Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. , 1993, Antiviral research.

[33]  M. Connelly,et al.  Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates , 1993, Antimicrobial Agents and Chemotherapy.

[34]  E. De Clercq,et al.  Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. , 1993, Antiviral research.

[35]  Erik De Clercq,et al.  HIV‐1‐specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase , 1993, Medicinal research reviews.

[36]  E. De Clercq,et al.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine , 1993, Antimicrobial Agents and Chemotherapy.

[37]  J. Mellors,et al.  A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). , 1993, Molecular pharmacology.

[38]  S. Readshaw,et al.  Use of isotopically chiral [4'-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract. , 1993, Chirality.

[39]  D. Earnshaw,et al.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus , 1992, Antimicrobial Agents and Chemotherapy.

[40]  N. Rousseau,et al.  Effect of beta-lactams on peptidoglycan metabolism of Haemophilus influenzae grown in animals , 1992, Antimicrobial Agents and Chemotherapy.

[41]  R. Whitley,et al.  Acyclovir: a decade later. , 1992, The New England journal of medicine.

[42]  J. C. Martin,et al.  Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. , 1992, Antiviral research.

[43]  D. Coen,et al.  A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells , 1992, Nature.

[44]  P. Miranda,et al.  Species Differences in the Metabolism and Disposition of Antiviral Nucleoside Analogues: 2. Zidovudine , 1992 .

[45]  A. Erice,et al.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir , 1991 .

[46]  R. Schinazi,et al.  Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. , 1991, Journal of medicinal chemistry.

[47]  E. De Clercq,et al.  Cellular uptake of phosphonylmethoxyalkylpurine derivatives. , 1991, Antiviral research.

[48]  R. T. Walker,et al.  Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro , 1991, Antimicrobial Agents and Chemotherapy.

[49]  E. De Clercq,et al.  9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Darby,et al.  Laboratory studies of herpes simplex virus strains resistant to acyclovir , 1991 .

[51]  D. Coen.  The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. , 1991, Antiviral research.

[52]  P. Halushka,et al.  Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. , 1991, Journal of medicinal chemistry.

[53]  Y. Cheng,et al.  Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. , 1991, The Journal of biological chemistry.

[54]  E. De Clercq,et al.  Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). , 1990, Virology.

[55]  L. Naesens,et al.  Anti‐retrovirus activity of 9‐(2‐phosphonylmethoxyethyl)adenine (pmea) in vivo increases when it is less frequently administered , 1990, International journal of cancer.

[56]  M. Rösner,et al.  Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models. , 1990, Antiviral research.

[57]  J. C. Martin,et al.  Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy)ethylguanine (PMEG). , 1990, Antiviral research.

[58]  J. C. Martin,et al.  Synthesis and antiviral activity of (S)-9-[4-hydroxy-3-(phosphonomethoxy)butyl]guanine. , 1990, Journal of medicinal chemistry.

[59]  J. Vlach,et al.  Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. , 1990, Antiviral research.

[60]  I. Votruba,et al.  Inhibition of herpes simplex virus DNA polymerase by diphosphates of acyclic phosphonylmethoxyalkyl nucleotide analogues. , 1990, Antiviral research.

[61]  V. Vonka,et al.  Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. , 1990, Antiviral research.

[62]  T. Merigan,et al.  Antiviral Agents and Viral Diseases of Man , 1990 .

[63]  E. De Clercq,et al.  Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[64]  J. C. Martin,et al.  In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues. , 1990, Journal of the National Cancer Institute.

[65]  E. Clercq.  Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents. , 1990 .

[66]  I. Votruba,et al.  The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L1210 mouse leukemia cells. , 1990, Neoplasma.

[67]  R T Walker,et al.  Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. , 1989, Biochemical and biophysical research communications.

[68]  R T Walker,et al.  A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. , 1989, Journal of medicinal chemistry.

[69]  D. Sutton,et al.  Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir] , 1989, Antimicrobial Agents and Chemotherapy.

[70]  S. Phadtare,et al.  Nucleic acid derived allenols. Unusual analogs of nucleosides with antiretroviral activity , 1989 .

[71]  D. Campoli-Richards,et al.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1989, Drugs.

[72]  R. Hodge,et al.  Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells , 1989, Antimicrobial Agents and Chemotherapy.

[73]  E. De Clercq,et al.  (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication , 1988, Antimicrobial Agents and Chemotherapy.

[74]  M. Rösner,et al.  New prodrugs of acyclic nucleosides with antiviral activity. , 1988, Arzneimittel-Forschung.

[75]  T. Rn.  Management of genital herpes simplex infections. , 1988 .

[76]  H. Mitsuya,et al.  Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[77]  R. Boehme,et al.  Antiviral activity and mechanism of action of ganciclovir. , 1988, Reviews of infectious diseases.

[78]  E. De Clercq,et al.  Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents , 1988, Antimicrobial Agents and Chemotherapy.

[79]  D. Morris.  Antiviral chemotherapy for cytomegalovirus disease. , 1988, Journal of Antimicrobial Chemotherapy.

[80]  D. Sutton,et al.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals , 1988, Antimicrobial Agents and Chemotherapy.

[81]  R. Webb,et al.  Synthesis of (S)-N1-(3-hydroxy-2-phosphonylmethoxy)propylcytosine, (S)-HPMPC , 1988 .

[82]  R. T. Walker,et al.  Antiviral drug development : a multidisciplinary approach , 1988 .

[83]  R. T. Walker,et al.  Antiviral Drug Development , 1988, NATO ASI Series.

[84]  C. Crumpacker,et al.  Drugs five years later: acyclovir. , 1987, Annals of internal medicine.

[85]  E. De Clercq,et al.  Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. , 1987, Molecular pharmacology.

[86]  R. L. Jarvest,et al.  Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines. , 1987, Journal of medicinal chemistry.

[87]  D. Sutton,et al.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture , 1987, Antimicrobial Agents and Chemotherapy.

[88]  J. D. Karkas,et al.  Stereochemical considerations in the enzymatic phosphorylation and antiviral activity of acyclonucleosides. I. Phosphorylation of 2'-nor-2'-deoxyguanosine. , 1987, Biochimica et biophysica acta.

[89]  A. Holý,et al.  Synthesis of isomeric and enantiomeric O-phosphonylmethyl derivatives of 9-(2,3-dihydroxypropyl)adenine , 1987 .

[90]  D. Coen,et al.  A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[91]  G. Cloud,et al.  Increased rate of cytomegalovirus infection among parents of children attending day-care centers. , 1986, The New England journal of medicine.

[92]  R. Schooley,et al.  Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. , 1985, Annals of internal medicine.

[93]  D. Smee,et al.  Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses , 1985, Antimicrobial Agents and Chemotherapy.

[94]  J. D. Karkas,et al.  Synthesis and antiherpetic activity of (S)-, (R)-, and (+/-)-9-[(2,3-dihydroxy-1-propoxy)methyl]guanine, linear isomers of 2'-nor-2'-deoxyguanosine. , 1985, Journal of medicinal chemistry.

[95]  D. A. Eppstein,et al.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with gamma interferon against herpes simplex virus type 2 in mice. , 1985, Antiviral research.

[96]  C. Crumpacker,et al.  2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity. , 1985, Biochemical and biophysical research communications.

[97]  D. Nelson,et al.  Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[98]  T. Mcelwain,et al.  AMINO (HYDROXYETHOXYMETHYL) PURINE: A NEW WELL-ABSORBED PRODRUG OF ACYCLOVIR , 1984, The Lancet.

[99]  C. Bruggeman,et al.  Human cytomegalovirus induces a cellular deoxyguanosine kinase, also interacting with Acyclovir , 1984 .

[100]  P. de Miranda,et al.  6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[101]  D. A. Eppstein,et al.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice , 1984, Antimicrobial Agents and Chemotherapy.

[102]  Y. Cheng,et al.  Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. , 1984, Journal of Biological Chemistry.

[103]  P. Furman,et al.  Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U , 1984, Antimicrobial Agents and Chemotherapy.

[104]  J. Drach.  Purine Nucleoside Analogs as Antiviral Agents , 1984 .

[105]  R. T. Walker,et al.  Targets for the Design of Antiviral Agents , 1984, NATO ASI Series.

[106]  G. Elion,et al.  Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir. , 1983, The Journal of pharmacology and experimental therapeutics.

[107]  R. N. Brogden,et al.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. , 1983, Drugs.

[108]  Y. Cheng,et al.  Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. , 1983, The Journal of biological chemistry.

[109]  L. Gerald,et al.  A single-tube radioimmunoassay for the antiviral agent 2,6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U). , 1983, Analytical biochemistry.

[110]  L. M. Beacham,et al.  Conversion of 2,6-diamino-9-(2-hydroxyethoxymethyl)purine to acyclovir as catalyzed by adenosine deaminase. , 1983, Biochemical pharmacology.

[111]  E. Rollinson,et al.  Relative activities of acyclovir and BW759 against Aujeszky's disease and equine rhinopneumonitis viruses. , 1983, Antimicrobial Agents and Chemotherapy.

[112]  J. D. Karkas,et al.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. C. Martin,et al.  9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. , 1983, Journal of medicinal chemistry.

[114]  E. Huang,et al.  Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[115]  J. C. Martin,et al.  Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine , 1983, Antimicrobial Agents and Chemotherapy.

[116]  D. Henry,et al.  Nucleosides, nucleotides, and their biological applications : proceedings of the 5th international round table, October 20-22, 1982 , 1983 .

[117]  K. K. Ogilvie,et al.  Biologically active acyclonucleoside analogues. II. The synthesis of 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BIOLF-62) , 1982 .

[118]  J. D. Karkas,et al.  Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). , 1982, Biochemical and biophysical research communications.

[119]  K. K. Ogilvie,et al.  A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2 , 1982, Antimicrobial Agents and Chemotherapy.

[120]  G. Elion,et al.  Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate , 1979 .

[121]  H. Schaeffer,et al.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[122]  J. Estes,et al.  Stimulation of Cellular Thymidine Kinases by Human Cytomegalovirus , 1977, Journal of virology.

[123]  B. Kjessler.  NURSING NEEDS IN THE GERIATRIC WARD. , 1964, Lancet.

[124]  Bernard,et al.  Advances in Drug Research , 1964 .